Catalio Capital Management LP Sells 86,096 Shares of Natera, Inc. $NTRA

Catalio Capital Management LP trimmed its holdings in Natera, Inc. (NASDAQ:NTRA) by 58.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 62,273 shares of the medical research company’s stock after selling 86,096 shares during the quarter. Natera makes up approximately 2.6% of Catalio Capital Management LP’s holdings, making the stock its 15th biggest position. Catalio Capital Management LP’s holdings in Natera were worth $14,266,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Palladiem LLC bought a new position in Natera in the 4th quarter worth approximately $31,000. Bank of Jackson Hole Trust boosted its stake in Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares during the period. Kemnay Advisory Services Inc. bought a new position in Natera in the 4th quarter worth approximately $39,000. Flagship Harbor Advisors LLC bought a new position in Natera in the 4th quarter worth approximately $41,000. Finally, Greenline Wealth Management LLC bought a new position in Natera in the 4th quarter worth approximately $41,000. 99.90% of the stock is currently owned by institutional investors.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 41,124 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the sale, the chief executive officer owned 108,743 shares in the company, valued at approximately $24,035,465.29. This represents a 27.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $218.43, for a total value of $655,290.00. Following the sale, the insider owned 137,643 shares in the company, valued at $30,065,360.49. The trade was a 2.13% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 162,342 shares of company stock worth $35,283,396 in the last ninety days. Corporate insiders own 5.05% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on NTRA shares. Robert W. Baird set a $265.00 price target on Natera in a research note on Friday, May 8th. JPMorgan Chase & Co. increased their target price on Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Evercore reiterated an “outperform” rating and set a $270.00 target price on shares of Natera in a research report on Friday, May 8th. Wells Fargo & Company increased their target price on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Finally, Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.53.

Natera Stock Performance

NASDAQ NTRA opened at $226.44 on Thursday. The company has a market capitalization of $32.43 billion, a P/E ratio of -138.92 and a beta of 1.56. Natera, Inc. has a one year low of $131.81 and a one year high of $256.36. The stock has a 50 day moving average price of $207.35 and a 200-day moving average price of $215.50.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.